Azithramycine

Azithramycine is a lipid of Polyketides (PK) class. Azithramycine is associated with abnormalities such as Respiratory Tract Infections, Pneumonia, Lower respiratory tract infection, Infection and Nonspecific urethritis. The involved functions are known as Lysis, Selection, Genetic, Mutation, Relapse and Adaptation. Azithramycine often locates in Blood, Respiratory System, Genitourinary system, Back and Chest. The associated genes with Azithramycine are Genes, rRNA, Genome, RPL22 gene, OPRM1 gene and tryptic soy broth. The related lipids are Liposomes, Phosphatidylserines, Promega, Lipopolysaccharides and Steroids. The related experimental models are Mouse Model, Knock-out and Tissue Model.

Cross Reference

Introduction

To understand associated biological information of Azithramycine, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with Azithramycine?

Azithramycine is suspected in Infection, Pneumonia, Trachoma, Respiratory Tract Infections, Gonorrhea, Infectious disease of lung and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with Azithramycine

MeSH term MeSH ID Detail
Hemolysis D006461 131 associated lipids
Airway Obstruction D000402 13 associated lipids
Stomach Ulcer D013276 75 associated lipids
Diarrhea D003967 32 associated lipids
Diabetes Mellitus D003920 90 associated lipids
Hearing Loss, Sensorineural D006319 8 associated lipids
Otitis Media D010033 12 associated lipids
Carcinoma, Basal Cell D002280 6 associated lipids
Bacterial Infections D001424 21 associated lipids
Pain D010146 64 associated lipids
Per page 10 20 50 100 | Total 276

PubChem Associated disorders and diseases

What pathways are associated with Azithramycine

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with Azithramycine?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with Azithramycine?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with Azithramycine?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with Azithramycine?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with Azithramycine?

Mouse Model

Mouse Model are used in the study 'Azithromycin increases in vitro fibronectin production through interactions between macrophages and fibroblasts stimulated with Pseudomonas aeruginosa.' (Cory TJ et al., 2013), Mouse Model are used in the study 'Efficacy of azithromycin, clarithromycin and beta-lactam agents against experimentally induced bronchopneumonia caused by Haemophilus influenzae in mice.' (Miyazaki S et al., 2001), Mouse Model are used in the study 'Oral anti-pneumococcal activity and pharmacokinetic profiling of a novel peptide deformylase inhibitor.' (Gross M et al., 2004), Mouse Model are used in the study 'Inhibition of quorum sensing in Pseudomonas aeruginosa by azithromycin and its effectiveness in urinary tract infections.' (Bala A et al., 2011) and Mouse Model are used in the study 'Enhanced efficacy of single-dose versus multi-dose azithromycin regimens in preclinical infection models.' (Girard D et al., 2005).

Knock-out

Knock-out are used in the study 'Influence of rhlR and lasR on Polymyxin Pharmacodynamics in Pseudomonas aeruginosa and Implications for Quorum Sensing Inhibition with Azithromycin.' (Bulman ZP et al., 2017) and Knock-out are used in the study 'Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.' (Mulet X et al., 2009).

Tissue Model

Tissue Model are used in the study 'Development of a population pharmacokinetic model characterizing the tissue distribution of azithromycin in healthy subjects.' (Zheng S et al., 2014).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with Azithramycine

Download all related citations
Per page 10 20 50 100 | Total 4404
Authors Title Published Journal PubMed Link
Sher AA et al. [Interactions in the system of copper ion-azalide (azithromycin)]. 1994 Sep-Oct Antibiot. Khimioter. pmid:7695446
Iakovlev SV and Ukhin SA [Azithromycin: general properties and regimen optimization based on pharmacokinetic and pharmacological parameters]. 2003 Antibiot. Khimioter. pmid:12803047
Kuznetsova SM ["Sumamed in the treatment of urogenital infections"]. 1996 Antibiot. Khimioter. pmid:8929115
Skripkin IuK et al. [The problem of diagnosis and treatment of urogenital chlamydiosis in Russia]. 1996 Antibiot. Khimioter. pmid:8929120
Vasil'ev MM and Gazarian IIu [Clinico-laboratory evaluation of the effectiveness of azithromycin in the treatment of patients with Chlamydia and mixed Chlamydia-gonorrhea infections]. 1996 Antibiot. Khimioter. pmid:8929122
Bingen E et al. Activity of telithromycin against penicillin-resistant Streptococcus pneumoniae isolates recovered from French children with invasive and noninvasive infections. 2003 Antimicrob. Agents Chemother. pmid:12821495
Pettus K et al. In vitro assessment of dual drug combinations to inhibit growth of Neisseria gonorrhoeae. 2015 Antimicrob. Agents Chemother. pmid:25624328
Retsema J et al. Spectrum and mode of action of azithromycin (CP-62,993), a new 15-membered-ring macrolide with improved potency against gram-negative organisms. 1987 Antimicrob. Agents Chemother. pmid:2449865
Wondrack L et al. Clinical strain of Staphylococcus aureus inactivates and causes efflux of macrolides. 1996 Antimicrob. Agents Chemother. pmid:8849266
Nash KA and Inderlied CB Genetic basis of macrolide resistance in Mycobacterium avium isolated from patients with disseminated disease. 1995 Antimicrob. Agents Chemother. pmid:8592991
Bohte R et al. Levels of azithromycin and alpha-1 acid glycoprotein in serum in patients with community-acquired pneumonia. 1995 Antimicrob. Agents Chemother. pmid:8593024
Beringer P et al. Absolute bioavailability and intracellular pharmacokinetics of azithromycin in patients with cystic fibrosis. 2005 Antimicrob. Agents Chemother. pmid:16304166
Ulrich M et al. Moxifloxacin and azithromycin but not amoxicillin protect human respiratory epithelial cells against streptococcus pneumoniae in vitro when administered up to 6 hours after challenge. 2005 Antimicrob. Agents Chemother. pmid:16304181
Girard AE et al. Pharmacokinetic and in vivo studies with azithromycin (CP-62,993), a new macrolide with an extended half-life and excellent tissue distribution. 1987 Antimicrob. Agents Chemother. pmid:2830841
Chang HR and Pechère JC In vitro effects of four macrolides (roxithromycin, spiramycin, azithromycin [CP-62,993], and A-56268) on Toxoplasma gondii. 1988 Antimicrob. Agents Chemother. pmid:2837140
Vallée E et al. Activity and local delivery of azithromycin in a mouse model of Haemophilus influenzae lung infection. 1992 Antimicrob. Agents Chemother. pmid:1324644
Merchan LM et al. Pharmacokinetics, microbial response, and pulmonary outcomes of multidose intravenous azithromycin in preterm infants at risk for Ureaplasma respiratory colonization. 2015 Antimicrob. Agents Chemother. pmid:25385115
Mertens JC et al. Double-blind randomized study comparing the efficacies and safeties of a short (3-day) course of azithromycin and a 5-day course of amoxicillin in patients with acute exacerbations of chronic bronchitis. 1992 Antimicrob. Agents Chemother. pmid:1324645
Hammerschlag MR et al. In vitro activities of azithromycin, clarithromycin, L-ofloxacin, and other antibiotics against Chlamydia pneumoniae. 1992 Antimicrob. Agents Chemother. pmid:1324650
Feola DJ et al. Azithromycin alters macrophage phenotype and pulmonary compartmentalization during lung infection with Pseudomonas. 2010 Antimicrob. Agents Chemother. pmid:20231397
Ednie LM et al. Comparative activities of clarithromycin, erythromycin, and azithromycin against penicillin-susceptible and penicillin-resistant pneumococci. 1996 Antimicrob. Agents Chemother. pmid:8843313
Bonnet M and Van der Auwera P In vitro and in vivo intraleukocytic accumulation of azithromycin (CP-62, 993) and its influence on ex vivo leukocyte chemiluminescence. 1992 Antimicrob. Agents Chemother. pmid:1329619
Hultén K et al. New pharmacokinetic in vitro model for studies of antibiotic activity against intracellular microorganisms. 1996 Antimicrob. Agents Chemother. pmid:9124830
Koletar SL et al. Azithromycin as treatment for disseminated Mycobacterium avium complex in AIDS patients. 1999 Antimicrob. Agents Chemother. pmid:10582873
Cynamon MH and Klemens SP Activity of azithromycin against Mycobacterium avium infection in beige mice. 1992 Antimicrob. Agents Chemother. pmid:1329622
Marchisio P et al. Comparative study of once-weekly azithromycin and once-daily amoxicillin treatments in prevention of recurrent acute otitis media in children. 1996 Antimicrob. Agents Chemother. pmid:9124831
Jacobsson S et al. Activity of the Novel Pleuromutilin Lefamulin (BC-3781) and Effect of Efflux Pump Inactivation on Multidrug-Resistant and Extensively Drug-Resistant Neisseria gonorrhoeae. 2017 Antimicrob. Agents Chemother. pmid:28893785
Zarantonelli L et al. Decreased azithromycin susceptibility of Neisseria gonorrhoeae due to mtrR mutations. 1999 Antimicrob. Agents Chemother. pmid:10508026
Seyama S et al. Amino Acid Substitution in the Major Multidrug Efflux Transporter Protein AcrB Contributes to Low Susceptibility to Azithromycin in Haemophilus influenzae. 2017 Antimicrob. Agents Chemother. pmid:28848006
Koetsveld J et al. Susceptibility of the Relapsing-Fever Spirochete Borrelia miyamotoi to Antimicrobial Agents. 2017 Antimicrob. Agents Chemother. pmid:28674060
Tateda K et al. Direct evidence for antipseudomonal activity of macrolides: exposure-dependent bactericidal activity and inhibition of protein synthesis by erythromycin, clarithromycin, and azithromycin. 1996 Antimicrob. Agents Chemother. pmid:8891128
Kemp MW et al. Maternal intravenous administration of azithromycin results in significant fetal uptake in a sheep model of second trimester pregnancy. 2014 Antimicrob. Agents Chemother. pmid:25155606
Hunt Gerardo S et al. Comparison of Etest to broth microdilution method for testing Streptococcus pneumoniae susceptibility to levofloxacin and three macrolides. 1996 Antimicrob. Agents Chemother. pmid:8891154
Zheng S et al. Development of a population pharmacokinetic model characterizing the tissue distribution of azithromycin in healthy subjects. 2014 Antimicrob. Agents Chemother. pmid:25155592
Descours G et al. Ribosomal Mutations Conferring Macrolide Resistance in Legionella pneumophila. 2017 Antimicrob. Agents Chemother. pmid:28069647
Ng LK et al. Mutation in 23S rRNA associated with macrolide resistance in Neisseria gonorrhoeae. 2002 Antimicrob. Agents Chemother. pmid:12183262
Prunier AL et al. Clinical isolates of Staphylococcus aureus with ribosomal mutations conferring resistance to macrolides. 2002 Antimicrob. Agents Chemother. pmid:12183270
Engel JN Azithromycin-induced block of elementary body formation in Chlamydia trachomatis. 1992 Antimicrob. Agents Chemother. pmid:1280057
Saini H et al. Azithromycin-Ciprofloxacin-Impregnated Urinary Catheters Avert Bacterial Colonization, Biofilm Formation, and Inflammation in a Murine Model of Foreign-Body-Associated Urinary Tract Infections Caused by Pseudomonas aeruginosa. 2017 Antimicrob. Agents Chemother. pmid:28031194
Binet R and Maurelli AT Frequency of development and associated physiological cost of azithromycin resistance in Chlamydia psittaci 6BC and C. trachomatis L2. 2007 Antimicrob. Agents Chemother. pmid:17908942
Collins SA et al. Cephalosporin-3'-Diazeniumdiolate NO Donor Prodrug PYRRO-C3D Enhances Azithromycin Susceptibility of Nontypeable Haemophilus influenzae Biofilms. 2017 Antimicrob. Agents Chemother. pmid:27919896
Walsh M et al. In vitro evaluation of CP-62,993, erythromycin, clindamycin, and tetracycline against Chlamydia trachomatis. 1987 Antimicrob. Agents Chemother. pmid:3038010
Starner TD et al. Subinhibitory concentrations of azithromycin decrease nontypeable Haemophilus influenzae biofilm formation and Diminish established biofilms. 2008 Antimicrob. Agents Chemother. pmid:17954687
Brieland JK et al. Efficacy of SCH27899 in an animal model of Legionnaires' disease using immunocompromised A/J mice. 2000 Antimicrob. Agents Chemother. pmid:10770771
Turcinov D et al. Failure of azithromycin in treatment of Brill-Zinsser disease. 2000 Antimicrob. Agents Chemother. pmid:10817744
Luke DR et al. Safety, toleration, and pharmacokinetics of intravenous azithromycin. 1996 Antimicrob. Agents Chemother. pmid:8913468
Tsitsika A et al. Single-oral-dose azithromycin prophylaxis against experimental streptococcal or staphylococcal aortic valve endocarditis. 2000 Antimicrob. Agents Chemother. pmid:10817749
Scorneaux B et al. Effect of recombinant human gamma interferon on intracellular activities of antibiotics against Listeria monocytogenes in the human macrophage cell line THP-1. 1996 Antimicrob. Agents Chemother. pmid:8723471
Olsen KM et al. Intrapulmonary pharmacokinetics of azithromycin in healthy volunteers given five oral doses. 1996 Antimicrob. Agents Chemother. pmid:8913469
Bin XX et al. Effect of azithromycin plus rifampin versus amoxicillin alone on eradication and inflammation in the chronic course of Chlamydia pneumoniae pneumonitis in mice. 2000 Antimicrob. Agents Chemother. pmid:10817751
Kuo CC et al. In vitro activities of azithromycin, clarithromycin, and other antibiotics against Chlamydia pneumoniae. 1996 Antimicrob. Agents Chemother. pmid:8913488
Pacifico L et al. Comparative efficacy and safety of 3-day azithromycin and 10-day penicillin V treatment of group A beta-hemolytic streptococcal pharyngitis in children. 1996 Antimicrob. Agents Chemother. pmid:8849215
Galarza PG et al. New mutation in 23S rRNA gene associated with high level of azithromycin resistance in Neisseria gonorrhoeae. 2010 Antimicrob. Agents Chemother. pmid:20123998
Mukherjee P et al. Emergence of high-level azithromycin resistance in Campylobacter jejuni isolates from pediatric diarrhea patients in Kolkata, India. 2014 Antimicrob. Agents Chemother. pmid:24777098
Jaruratanasirikul S et al. Distribution of azithromycin into brain tissue, cerebrospinal fluid, and aqueous humor of the eye. 1996 Antimicrob. Agents Chemother. pmid:8851625
Achard A et al. Emergence of macrolide resistance gene mph(B) in Streptococcus uberis and cooperative effects with rdmC-like gene. 2008 Antimicrob. Agents Chemother. pmid:18519724
Zasowski E et al. Relationship between time to clinical response and outcomes among Pneumonia Outcomes Research Team (PORT) risk class III and IV hospitalized patients with community-acquired pneumonia who received ceftriaxone and azithromycin. 2014 Antimicrob. Agents Chemother. pmid:24752270
Rouse MS et al. Efficacy of azithromycin or clarithromycin for prophylaxis of viridans group streptococcus experimental endocarditis. 1997 Antimicrob. Agents Chemother. pmid:9257739
Wong MH et al. Emergence of clinical Salmonella enterica serovar Typhimurium isolates with concurrent resistance to ciprofloxacin, ceftriaxone, and azithromycin. 2014 Antimicrob. Agents Chemother. pmid:24752251
Carryn S et al. Comparative intracellular (THP-1 macrophage) and extracellular activities of beta-lactams, azithromycin, gentamicin, and fluoroquinolones against Listeria monocytogenes at clinically relevant concentrations. 2002 Antimicrob. Agents Chemother. pmid:12069960
Jeong BH et al. Peak Plasma Concentration of Azithromycin and Treatment Responses in Mycobacterium avium Complex Lung Disease. 2016 Antimicrob. Agents Chemother. pmid:27480854
Marvig RL et al. Mutations in 23S rRNA confer resistance against azithromycin in Pseudomonas aeruginosa. 2012 Antimicrob. Agents Chemother. pmid:22644032
Ohtani H et al. Comparative pharmacodynamic analysis of Q-T interval prolongation induced by the macrolides clarithromycin, roxithromycin, and azithromycin in rats. 2000 Antimicrob. Agents Chemother. pmid:10991836
Erhardt W et al. Establishing criteria for assessment of efficacy of antimicrobial agents in acute otitis media. 2000 Antimicrob. Agents Chemother. pmid:11012390
Cigana C et al. Azithromycin selectively reduces tumor necrosis factor alpha levels in cystic fibrosis airway epithelial cells. 2007 Antimicrob. Agents Chemother. pmid:17210769
Visalli MA et al. Susceptibility of penicillin-susceptible and -resistant pneumococci to dirithromycin compared with susceptibilities to erythromycin, azithromycin, clarithromycin, roxithromycin, and clindamycin. 1997 Antimicrob. Agents Chemother. pmid:9303375
Farrell DJ et al. Results from the Solithromycin International Surveillance Program (2014). 2016 Antimicrob. Agents Chemother. pmid:27044551
Niki Y et al. In vitro and in vivo activities of azithromycin, a new azalide antibiotic, against chlamydia. 1994 Antimicrob. Agents Chemother. pmid:7840560
Freeman CD et al. Intracellular and extracellular penetration of azithromycin into inflammatory and noninflammatory blister fluid. 1994 Antimicrob. Agents Chemother. pmid:7840585
Chinh NT et al. A randomized controlled comparison of azithromycin and ofloxacin for treatment of multidrug-resistant or nalidixic acid-resistant enteric fever. 2000 Antimicrob. Agents Chemother. pmid:10858343
Miltner EC and Bermudez LE Mycobacterium avium grown in Acanthamoeba castellanii is protected from the effects of antimicrobials. 2000 Antimicrob. Agents Chemother. pmid:10858369
Sugimura M et al. Macrolide antibiotic-mediated downregulation of MexAB-OprM efflux pump expression in Pseudomonas aeruginosa. 2008 Antimicrob. Agents Chemother. pmid:18676884
Liu P et al. Comparison of azithromycin pharmacokinetics following single oral doses of extended-release and immediate-release formulations in children with acute otitis media. 2011 Antimicrob. Agents Chemother. pmid:21859932
Shima K et al. Activities of first-choice antimicrobials against gamma interferon-treated Chlamydia trachomatis differ in hypoxia. 2013 Antimicrob. Agents Chemother. pmid:23478971
Pfefferkorn ER and Borotz SE Comparison of mutants of Toxoplasma gondii selected for resistance to azithromycin, spiramycin, or clindamycin. 1994 Antimicrob. Agents Chemother. pmid:8141576
Bermudez LE et al. Rifabutin and sparfloxacin but not azithromycin inhibit binding of Mycobacterium avium complex to HT-29 intestinal mucosal cells. 1994 Antimicrob. Agents Chemother. pmid:8067766
Agacfidan A et al. In vitro activity of azithromycin (CP-62,993) against Chlamydia trachomatis and Chlamydia pneumoniae. 1993 Antimicrob. Agents Chemother. pmid:8239579
Goodman CD et al. Chemobiosynthesis of new antimalarial macrolides. 2013 Antimicrob. Agents Chemother. pmid:23208707
Tomazic J et al. In vivo administration of azithromycin affects lymphocyte activity in vitro. 1993 Antimicrob. Agents Chemother. pmid:8239585
Kim MK et al. Bactericidal effect and pharmacodynamics of cethromycin (ABT-773) in a murine pneumococcal pneumonia model. 2002 Antimicrob. Agents Chemother. pmid:12234843
Allen GP and Harris KA Resistance Selection in Shigella flexneri by Azithromycin, Ceftriaxone, Ciprofloxacin, Levofloxacin, and Moxifloxacin. 2017 Antimicrob. Agents Chemother. pmid:28483960
Barry AL et al. In vitro activities of azithromycin (CP 62,993), clarithromycin (A-56268; TE-031), erythromycin, roxithromycin, and clindamycin. 1988 Antimicrob. Agents Chemother. pmid:2840016
Araujo FG et al. Azithromycin, a macrolide antibiotic with potent activity against Toxoplasma gondii. 1988 Antimicrob. Agents Chemother. pmid:2840017
Alder JD et al. Dynamics of clarithromycin and azithromycin efficacies against experimental Haemophilus influenzae pulmonary infection. 1998 Antimicrob. Agents Chemother. pmid:9736568
Caronzolo D et al. Glucocorticoids increase in vitro and in vivo activities of antibiotics against Chlamydophila pneumoniae. 2004 Antimicrob. Agents Chemother. pmid:15561871
Carter G et al. A subinhibitory concentration of clarithromycin inhibits Mycobacterium avium biofilm formation. 2004 Antimicrob. Agents Chemother. pmid:15561879
Pereira MR et al. In vivo and in vitro antimalarial properties of azithromycin-chloroquine combinations that include the resistance reversal agent amlodipine. 2011 Antimicrob. Agents Chemother. pmid:21464242
Roord JJ et al. Prospective open randomized study comparing efficacies and safeties of a 3-day course of azithromycin and a 10-day course of erythromycin in children with community-acquired acute lower respiratory tract infections. 1996 Antimicrob. Agents Chemother. pmid:9124837
Wenisch C et al. Effect of single oral dose of azithromycin, clarithromycin, and roxithromycin on polymorphonuclear leukocyte function assessed ex vivo by flow cytometry. 1996 Antimicrob. Agents Chemother. pmid:8878577
Gnarpe J et al. In vitro activities of azithromycin and doxycycline against 15 isolates of Chlamydia pneumoniae. 1996 Antimicrob. Agents Chemother. pmid:8843291
Schroeck JL et al. Factors associated with antibiotic misuse in outpatient treatment for upper respiratory tract infections. 2015 Antimicrob. Agents Chemother. pmid:25870064
Dreses-Werringloer U et al. Effects of azithromycin and rifampin on Chlamydia trachomatis infection in vitro. 2001 Antimicrob. Agents Chemother. pmid:11600348
Tateda K et al. Azithromycin inhibits quorum sensing in Pseudomonas aeruginosa. 2001 Antimicrob. Agents Chemother. pmid:11353657
Gödeke J et al. Recycling of peptidyl-tRNAs by peptidyl-tRNA hydrolase counteracts azithromycin-mediated effects on Pseudomonas aeruginosa. 2013 Antimicrob. Agents Chemother. pmid:23318806
Ouadrhiri Y et al. Mechanism of the intracellular killing and modulation of antibiotic susceptibility of Listeria monocytogenes in THP-1 macrophages activated by gamma interferon. 1999 Antimicrob. Agents Chemother. pmid:10223943
Könönen E et al. beta-lactamase production and antimicrobial susceptibility of oral heterogeneous Fusobacterium nucleatum populations in young children. 1999 Antimicrob. Agents Chemother. pmid:10223950
Nagaoka K et al. Macrolides inhibit Fusobacterium nucleatum-induced MUC5AC production in human airway epithelial cells. 2013 Antimicrob. Agents Chemother. pmid:23380724
Bergman KL et al. Antimicrobial activities and postantibiotic effects of clarithromycin, 14-hydroxy-clarithromycin, and azithromycin in epithelial cell lining fluid against clinical isolates of haemophilus influenzae and Streptococcus pneumoniae. 1999 Antimicrob. Agents Chemother. pmid:10223956
Akova M et al. In vitro activities of antibiotics alone and in combination against Brucella melitensis at neutral and acidic pHs. 1999 Antimicrob. Agents Chemother. pmid:10223958
Edelstein PH et al. In vitro activity of gemifloxacin (SB-265805, LB20304a) against Legionella pneumophila and its pharmacokinetics in guinea pigs with L. pneumophila pneumonia. 2001 Antimicrob. Agents Chemother. pmid:11451675